- Home
- IMCC vs OGEN Comparison
IMCC vs OGEN Comparison
Compare IMCC & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- OGEN
- Stock Information
- Founded
- IMCC 1980
- OGEN 1996
- Country
- IMCC Israel
- OGEN United States
- Employees
- IMCC N/A
- OGEN N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- OGEN Health Care
- Exchange
- IMCC Nasdaq
- OGEN Nasdaq
- Market Cap
- IMCC 5.3M
- OGEN 4.6M
- IPO Year
- IMCC N/A
- OGEN N/A
- Fundamental
- Price
- IMCC $1.66
- OGEN $0.20
- Analyst Decision
- IMCC
- OGEN
- Analyst Count
- IMCC 0
- OGEN 0
- Target Price
- IMCC N/A
- OGEN N/A
- AVG Volume (30 Days)
- IMCC 11.4K
- OGEN 351.6K
- Earning Date
- IMCC 05-15-2025
- OGEN 05-09-2025
- Dividend Yield
- IMCC N/A
- OGEN N/A
- EPS Growth
- IMCC N/A
- OGEN N/A
- EPS
- IMCC N/A
- OGEN N/A
- Revenue
- IMCC $37,894,737.00
- OGEN N/A
- Revenue This Year
- IMCC $47.12
- OGEN N/A
- Revenue Next Year
- IMCC $12.83
- OGEN N/A
- P/E Ratio
- IMCC N/A
- OGEN N/A
- Revenue Growth
- IMCC 12.68
- OGEN N/A
- 52 Week Low
- IMCC $1.29
- OGEN $0.16
- 52 Week High
- IMCC $5.10
- OGEN $3.43
- Technical
- Relative Strength Index (RSI)
- IMCC 53.36
- OGEN 52.52
- Support Level
- IMCC $1.56
- OGEN $0.18
- Resistance Level
- IMCC $1.71
- OGEN $0.22
- Average True Range (ATR)
- IMCC 0.17
- OGEN 0.02
- MACD
- IMCC 0.01
- OGEN 0.00
- Stochastic Oscillator
- IMCC 55.32
- OGEN 66.67
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.